Stroke in otherwise healthy young people linked to Coronavirus

0

A high incidence of stroke seen in younger patients who were otherwise healthy linked to COVID-19 infection

Young patients with no risk factors for stroke may have an increased risk if they have contracted COVID-19. Many of these healthy young adults may not have any symptoms of the disease. Most of these strokes were major stroke involving large areas of the brain in both hemispheres, hence associated with increased mortality.

Researchers analyzed 14 patients presenting with stroke from March 20th until April 10th at their institutions. Eight patients were male, six were female, 50%, did not know they had the coronavirus, while the remainder were already being treated for other symptoms of the disease when they developed a stroke. The strokes they observed were unlike what they usually see. 

We were seeing patients in their 30s, 40s and 50s with massive strokes, the kind that we typically see in patients in their 70s and 80s

“We were seeing patients in their 30s, 40s and 50s with massive strokes, the kind that we typically see in patients in their 70s and 80s,” said lead author,  Pascal Jabbour, MD, Chief of the Division of Neurovascular Surgery and Endovascular Surgery at  Jefferson Health. 

Some highlights of the paper :

1. Patients with signs of stroke were delaying coming to the hospital for fear of getting the coronavirus. There’s a small window of time in which strokes are treatable, so delays can be life threatening.

2. The mortality rate in these covid-19 stroke patients is 42.8%. The typical mortality from stroke is around 5 to 10%.

3. 42% of the stroke coronavirus positive patients studied were under the age of 50. Most strokes, over 75% of all strokes in the US, occur in people over the age of 65.

4. The incidence of coronavirus in the stroke population was 31.5%, according to this sample of patients.

5. Patients observed had strokes in large vessels, in both hemispheres of the brain, and in both arteries and veins of the brain – all of these observations are unusual in stroke patients.

“Young people, who may not know they have the coronavirus, are developing clots that cause major stroke. Our observations, though preliminary, can serve as a warning for medical personnel on the front lines, and for all of those at home,” said Dr. Jabbour. “Stroke is occurring in people who don’t know they have COVID-19, as well as those who feel sick from their infections. We need to be vigilant and respond quickly to signs of stroke.”

 

Two retractions, one database – a medical scandal in COVID19 season

0

Two studies based on data from the same database have been retracted leaving The Lancet and the New England Journal of Medicine red-faced

 

In a bit of a scandal, two prominent medical journals have retracted two studies that drew from the database of a Chicago-based company, citing problems with data quality.

The Lancet wrote: “Today, three of the authors of the paper, “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis”, have retracted their study. They were unable to complete an independent audit of the data underpinning their analysis. As a result, they have concluded that they “can no longer vouch for the veracity of the primary data sources.” The Lancet takes issues of scientific integrity extremely seriously, and there are many outstanding questions about Surgisphere and the data that were allegedly included in this study. Following guidelines from the Committee on Publication Ethics (COPE) and International Committee of Medical Journal Editors (ICMJE), institutional reviews of Surgisphere’s research collaborations are urgently needed.” 

At the Centre of ask this is Surgisphere, whose registry “an aggregation of the deidentified electronic health records of customers of QuartzClinical…”

The World Health Organisation has already revised its decision on HCQ and reinstated it as one of the arms of the multi country SOLIDARITY trial. The decision to suspend that arm was taken after the study in question.

In another development the New England Journal of Medicine too has printed a retraction note for a study it printed last month. The note reads: “Because all the authors were not granted access to the raw data and the raw data could not be made available to a third-party auditor, we are unable to validate the primary data sources underlying our article, “Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. We therefore request that the article be retracted. We apologize to the editors and to readers of the Journal for the difficulties that this has caused.” The two studies have three authors in common.

At the Centre of ask this is Surgisphere, whose registry “an aggregation of the deidentified electronic health records of customers of QuartzClinical, Surgisphere’s machine learning program and data analytics platform”. The company has vouched for the integrity of its own data even though it has cited client confidentiality agreements to not give access to it.

“One of the core principals at Surgisphere is based around data integrity. Another is centered on data security. Our entire ISO 9001:2015 and ISO 27001:2013 certificate and various audits that we have completed all focus on these two foundations of the company, and the data acquisition, warehousing, analytics, and reporting processes that relate to them. It is vitally important that our colleagues around the world understand the validity of our database as it relates to those functions, especially where the data comes from, the database, and the statistical analysis,” the company said in a statement following an earlier expression of concern by The Lancet on the HCQ study.

Anti-acidity drug may curb COVID-19 symptoms in mild to moderate disease

0

A widely available and inexpensive anti-acidity drug reduced COVID-19 symptoms within 1-2 days in mild to moderate disease 

A widely available and inexpensive anti-acidity drug that is used to ease the symptoms of indigestion may control COVID-19 symptoms in those whose disease doesn’t require admission to hospital, suggest the findings of a case series, published online in the journal Gut.

The effects were felt within 24 to 48 hours of taking famotidine. Famotidine belongs to a class of drugs known as histamine-2 receptor antagonists, which reduce the amount of stomach acid produced. Famotidine can be taken in doses of 20-160 mg, up to four times a day, for the treatment of acid reflux and heartburn.

In this study, a patient-reported symptom tracking method used for patients with cancer was adapted for patients with COVID-19. Researchers developed a 4-point scale for six common COVID-19 associated symptoms – cough; shortness of breath; fatigue; headache and loss of taste/smell as well as general unwellness that patients score every day. 

All 10 patients said that symptoms quickly improved within 24-48 hours of starting famotidine and had mostly cleared up after 14 days

The report included 10 people (6 men; 4 women) aged 23 to 71 years, who developed COVID-19 infection. Seven of the patients tested positive for COVID-19, using a swab test; two had antibodies to the infection; and one patient wasn’t tested but was diagnosed with the infection by a doctor.

They had a diverse range of ethnic backgrounds and known risk factors for COVID-19 severity, including high blood pressure and obesity. All started taking famotidine when they were feeling very poorly with COVID-19. The most frequently used dose was 80 mg taken three times a day, with the average treatment period lasting 11 days, but ranging from 5 to 21 days.

All 10 patients said that symptoms quickly improved within 24-48 hours of starting famotidine and had mostly cleared up after 14 days. Improvement was evident across all symptom categories assessed, but respiratory symptoms, such as cough and shortness of breath, improved more rapidly than systemic symptoms, such as fatigue. Three patients experienced mild but temporary forgetfulness, a known side effect of the drug.

“Our case series suggests, but does not establish, a benefit from famotidine treatment in outpatients with COVID-19,” authors cautioned. A clinical trial, testing the combination of famotidine with the antimalarial drug hydroxychloroquine in patients admitted to hospital with COVID-19, is already under way.

Once validated, the patient-reported symptom tracking method will be a key component in a clinical trial that is “double-blind,” meaning that neither patient nor doctor know whether the patient is getting the test drug or a placebo (standard therapy) until the trial is completed. 

India pledges $15 mn to GAVI, the vaccine alliance: Modi

0

Prime Minister Narendra Modi while addressing the virtual Global Vaccine Summit announced that India will donate $15 mn to GAVI

India has today pledged 15 Million US Dollars to Gavi, the international vaccine alliance.

Prime Minister Narendra Modi announced this while addressing the virtual Global Vaccine Summit hosted by UK Prime Minister Boris Johnson in which over 50 ​countries – business leaders, UN agencies, civil society, government ministers, Heads of State and country leaders participated.

In his address the Prime Minister said India stands in solidarity with the World in these challenging times.

Prime Minister said India’s support to GAVI is not only financial but that India’s huge demand also brings down the Global price of vaccines for all, saving almost 400 Million Dollars for GAVI over the past five years

Modi said, India’s civilization teaches to see the world as one family and that during this pandemic it had tried to live upto this teaching. He said India did it so by sharing the country’s available stocks of medicines with over 120 countries, by forging a common response strategy in its immediate neighborhood and by providing specific support to countries that sought it, while also protecting India’s own vast population.

Prime Minister said the COVID19 pandemic, in someways, has exposed the limitations of global cooperation and that for the first time in recent history, the human kind faces a clear common enemy.

Referring to Gavi, he said it is not just a global alliance but also a symbol of global solidarity and a reminder of that by helping others we can also help ourselves.

He said India has a vast population and limited health facilities and that it understands the importance of immunization.

Prime Minister said that one of the first programmes launched by his government was Mission Indradhanush, which aims to ensure full vaccination of the country’s children and pregnant women, including those in the remote parts of the vast nation.

He said in order to expand protection, India has added six new vaccines to its National Immunization Programme.

Prime Minister elaborated that India had digitized its entire vaccine supply line and developed an electronic vaccine intelligence network to monitor the integrity of its cold chain.

These innovations are ensuring the availability of safe and potent vaccines in the right quantities at the right time till the last mile, he said

Prime Minister said India is also the World’s foremost producer of vaccines and that it is fortunate to contribute to the immunization of about 60 percent of the World’s children.

Shri Modi said India recognizes and values the work of GAVI, that is why it became a donor to GAVI while still being eligible for GAVI support.

Prime Minister said India’s support to GAVI is not only financial but that India’s huge demand also brings down the Global price of vaccines for all, saving almost 400 Million Dollars for GAVI over the past five years.

Prime Minister reiterated that India stands in solidarity with the world along with its proven capacity to produce quality medicines and vaccines at low cost, its own domestic experience in rapidly expanding immunization and its considerable scientific research talent.

India not only has the capacity to contribute to the global health efforts, but also has the will to do so in a spirit of sharing and caring, he said.

One in every four samples tested for COVID19 in Delhi is positive

0

For the last week Delhi’s positivity for COVID19 continued to be over 25%; in some districts it was as high as 38%

Delhi’s high rate of positivity of COVID19 cases continue to ring alarm bells.

“As the number of cases and fatality rises in Delhi, it needs to ramp up testing coupled with aggressive surveillance, contact tracing and stringent containment and perimeter control activities”, Union health minister Dr. Harsh Vardhan said on Thursday. He chaired a high-level meeting through video conferencing (VC) to review the preparedness for prevention and control of COVID-19, here today.

He was joined by Ashwini Kumar Choubey, MoS (HFW), Anil Baijal, Lieutenant Governor of Delhi and Satyendra Jain, Health Minister of Delhi.

As all districts of UT of Delhi are now affected by COVID-19, Dr Harsh Vardhan pointed out that “the rising cases, high positivity rates and low testing levels in many districts are worrisome”. While the average testing/million population in Delhi was 2018, some districts such as north east (517 tests/million population) and South east (506 tests/million population) were far below.

While the average testing/million population in Delhi was 2018, some districts such as north east (517 tests/million population) and South east (506 tests/million population) were far below

While the UT’s positivity rate of last week was 25.7%, several districts reported figures above 38%, he said. The high rate of infection in the health care workers was also a serious issue, he added. It indicates poor infection prevention control practices in health care settings and needs to be attended to on priority, he pointed out.

He underscored the immediate need and importance of scaling up of testing with health infrastructure enhancements along with better clinical management of the COVID-19 cases for effective case management and reduction of fatality rate. He also pointed that bed availability was to be rapidly increased in view of current rapid rise of cases along with avoiding unnecessary delay in admission of cases.

“As a significant proportion are on home isolation, all efforts for timely response in terms of testing, triaging and shifting of patients to the required level of Dedicated COVID facility is important to avoid mortality”, he stated.

The elderly and vulnerable population, such as those with underlying co-morbidities, need to be identified and protected, he said, adding that provisioning of institutional quarantine to vulnerable populations in large clusters where home isolation is not deemed effective, needs attention too.

 

How radiologists can reduce risk of COVID19 for patients & staff

0

With SARS-COV2 on the prowl and hospitals trying to return to the new normal, some practical solutions to reduce COVID19 risk for radiologists

 

An open-access article in the American Journal of Roentgenology (AJR) details myriad practical updates that radiologists performing cross-sectional interventional procedures should institute to minimize risks for patients and imaging personnel alike during the coronavirus disease (COVID-19) pandemic.

“Cross-sectional interventional procedures are performed under CT, ultrasound, fluoroscopy, or MRI guidance and include fluid aspiration, (thoracentesis, paracentesis, and fluid collections), drainage catheter placement, percutaneous biopsy, and tumor ablation,” explained lead author Ghaneh Fananapazir at the University of California Davis Medical Center.

All of these procedures require appropriate donning and doffing of personal protective equipment by every member of the IR team–physician, trainee, nurse, technologist–and some procedures may require admitting the patient for management of postprocedure complications, necessitating a hospital bed and auxiliary resources.

Ideally, all anticipated IT tray supplies should be acquired before the procedure commences, covered with a sterile plastic drape, and opened only to the extent needed

Thus, for procedural delays that will not adversely affect patient outcome, Fananapazir and colleagues proposed the following tiered approach for both outpatient and inpatient scenarios: urgent procedures, procedures that should be performed within 2 weeks, procedures that should be performed within 2 months, and procedures that can safely be delayed 2 or 6 months.

“Each procedure request must be triaged into a tier on a case-by-case basis,” Fananapazir et al. warned, “because clinical circumstances can dictate one procedure as urgent, whereas different clinical data may render the same procedure safe to delay.” When considering any procedural delay, Fananapazir’s team strongly recommended consultation with the referring physician, who may have insights not available to the interventional radiologist.

Wherever possible, procedures should be performed bedside in COVID-19 units (or patient rooms, should no dedicated COVID-19 unit exist). Regarding ultrasound-guided procedures, specifically, a mobile ultrasound unit can be left in place in the ICU or the COVID-19 unit–“used for interventional procedures, guidance for vascular access, or point-of-care thoracic and nonthoracic ultrasound,” wrote Fananapazir et al. Ultrasound probes should be sterilized according to manufacturer guidelines.

Fananapazir’s team also cautioned against CT technologists or sonographers entering the procedure room. Ideally, all anticipated IT tray supplies should be acquired before the procedure commences, covered with a sterile plastic drape, and opened only to the extent needed.

Additionally, patient interaction during the informed consent interview can be limited by obtaining consent in the procedure room or using documented oral consent in the medical record. “Both of these modifications to the consent process are outside of standard regulated practice,” the authors of this AJR article noted, “therefore, establishment of hospital-wide frameworks may be needed.”

Pulmonary embolism is common among obese COVID-19 patients

0

Patients with COVID-19 infection with a BMI of 30 or higher are nearly three times more at risk for developing a pulmonary embolism

In a new study published in the journal Radiology, researchers found that every fifth COVID-19 patient who underwent a pulmonary CT angiography was diagnosed with pulmonary embolism (PE). They also found that obesity was a major risk factor for development of PE.

Pulmonary embolism occurs when a blood clot (thrombus) in a deep vein, usually in the legs, is dislodged and travels to the lungs where it blocks one or more vessels. This typically occurs if the vein wall is damaged, blood flow is too slow, or the blood becomes too thick. Symptoms including shortness of breath and chest pain resemble other diseases so the diagnosis is often missed, or the severity of the situation is underestimated, and many patients usually die before getting appropriate therapy.

In Europe, studies have shown that most cases of PE were diagnosed in patients admitted to the intensive care unit after being on a ventilator for several days.

The study included 328 COVID-19 patients who underwent a pulmonary CT angiography between March 16 and April 18 at Henry Ford’s acute care hospitals. 72 percent of PE diagnoses were made in patients who did not require ICU-level care, suggesting that timely diagnosis and use of blood thinners could have played a role in the treatment process.

Increased D-dimer and C-reactive protein lab markers, in conjunction with a rising oxygen requirement, may be a predictor of a pulmonary embolism, even when patients are receiving preventive blood thinners

“Based on our study, early detection of PE could further enhance and optimize treatment for patients first presenting in the Emergency Department,” said Pallavi Bhargava, M.D., an infectious diseases physician and co-author of the study. “We advise clinicians to think of PE as an additional complication early on during the admission of patients whose symptoms and lab results point to that condition.”

Key highlight of the study : 

  1. 22 percent of patients were found to have a pulmonary embolism.
  2. Patients with a BMI (body mass index) of 30 or higher are nearly three times more at risk for developing a pulmonary embolism. The ideal BMI for adults is 18.5 – 24.9.
  3. Patients on statin therapy prior to admission were less likely to develop a pulmonary embolism.
  4. Increased D-dimer and C-reactive protein lab markers, in conjunction with a rising oxygen requirement, may be a predictor of a pulmonary embolism, even when patients are receiving preventive blood thinners.

Researchers said early diagnosis of a life-threatening blood clot in the lungs could lead to faster treatment intervention in COVID-19 patients which in turn could reduce need for ICU care.

Convalescent plasma therapy effective in 76% COVID-19 patients, finds study

0

Convalescent plasma therapy is safe and improves outcome in three out of four COVID-19 patients, finds a new study

A new trial on convalescent plasma therapy found that convalescent plasma is a safe treatment option for patients with severe COVID-19 disease. Convalescent plasma therapy uses plasma  donated by recovered patients of COVID-19 to introduce antibodies in those under treatment. These antibodies are highly specific to the invading pathogen and work to eliminate the novel coronavirus from the patient’s body.

Results of this peer-reviewed trial showed that 19 out of 25 patients improved with the treatment and 11 were discharged from the hospital. There were no serious adverse side effects caused by the plasma transfusion and findings were published in the American Journal of Pathology

“While physician scientists around the world scrambled to test new drugs and treatments against the COVID-19 virus, convalescent serum therapy emerged as potentially one of the most promising strategies,” said James M. Musser, M.D., Ph.D., chair of the Department of Pathology and Genomic Medicine at Houston Methodist and the corresponding author on the study. “With no proven treatments or cures for COVID-19 patients, now was the time in our history to move ahead rapidly.”

Patients were treated under emergency use guidelines (eIND) from the U.S. Food and Drug Administration and then received approval from the FDA to open up the trial to more patients as an investigational new drug (IND). 

this trial revealed patient outcomes following plasma therapy were very similar to recently published results of patients treated on a compassionate-use basis with the antiviral drug remdesivir

Indian Council of Medical Research (ICMR) is also conducting a multicentric phase-2 trial using convalescent plasma on COVID-19 patients with moderate illness after three feasibility studies in about 20 severely ill patients found the therapy to be safe and able to resolve illness or improve the clinical symptoms. The trial will involve 452 patients in 21 hospitals with moderate COVID-19 illness. Half of the patients will be randomly assigned to receive convalescent plasma (226 participants) and the other half will receive standard care (control group). 

Convalescent plasma therapy has been tried in many viral diseases, like the 1918 Spanish Flu and more recently it was used with some success during the 2003 SARS pandemic and the 2009 influenza H1N1 pandemic. But a recent study of plasma therapy conducted in Guinea under the guidance of WHO with 84 Ebola-infected patients did not show any significant improvement in survival during the 2015 Ebola outbreak in Africa. 

Additional findings during this trial revealed patient outcomes following plasma therapy were very similar to recently published results of patients treated on a compassionate-use basis with the antiviral drug remdesivir. The research team also concluded that any observed complications were consistent with findings reported for COVID-19 disease progression and did not result from the plasma transfusions. 

Researchers are considering a randomized controlled trial to look more closely at variables such as timing of the transfusion after the onset of symptoms, the number and volume of transfusions adjusted for patient biometrics, antibody levels in donor plasma and numerous other parameters needed to effectively evaluate how to optimize this therapy. 

Masks, goggles and one metre distance keep COVID19 away: Lancet

0

Lancet study finds covering the nose, mouth and eyes, plus keeping a safe distance are the best recipe for prevention of COVID19

Keeping at least one metre from other people, wearing face coverings and eye protection could be the best way to reduce the chance of viral infection or transmission of COVID-19. This is the finding of a systematic review and meta-analysis synthesising all the available evidence from the scientific literature, published in The Lancet.

However, none of these interventions, even when properly used and combined, give complete protection from infection, and the authors note that some of the findings, particularly around face masks and eye protection, are supported by low-certainty evidence, with no completed randomised trials addressing COVID-19 for these interventions.

The study, conducted to inform WHO guidance documents, is the first time researchers have systematically examined the optimum use of these protective measures in both community and healthcare settings for COVID-19. The authors say it has immediate and important implications for curtailing the current COVID-19 pandemic and future waves by informing disease models, and standardising the definition of who has been ‘potentially exposed’ (ie, within 2 metres) for contact tracing.

COVID-19 is most commonly spread by respiratory droplets, especially when people cough and sneeze, entering through the eyes, nose, and mouth, either directly or by touching a contaminated surface

Many countries and regions have issued conflicting advice about physical distancing to reduce transmission of COVID-19, based on limited information. In addition, the questions of whether masks and eye coverings might reduce transmission of COVID-19 in the general population, and what the optimum use of masks in healthcare settings is, have been debated during the pandemic.

“Our findings are the first to synthesise all direct information on COVID-19, SARS, and MERS, and provide the currently best available evidence on the optimum use of these common and simple interventions to help “flatten the curve” and inform pandemic response efforts in the community”, says Professor Holger Schünemann from McMaster University in Canada, who co-led the research. “Governments and the public health community can use our results to give clear advice for community settings and healthcare workers on these protective measures to reduce infection risk.”

The currently best available evidence suggests that COVID-19 is most commonly spread by respiratory droplets, especially when people cough and sneeze, entering through the eyes, nose, and mouth, either directly or by touching a contaminated surface. At the moment, although there is consensus that SARS-CoV-2 mainly spreads through large droplets and contact, debate continues about the role of aerosol spreading.

For the current analysis, an international team of researchers did a systematic review of 172 observational studies assessing distance measures, face masks, and eye protection to prevent transmission between patients with confirmed or probable COVID-19, SARS, or MERS infection and individuals close to them (eg, caregivers, family, healthcare workers), up to May 3, 2020.

Pooled estimates from 44 comparative studies involving 25,697 participants were included in the meta-analysis. Of these, 7 studies focused on COVID-19 (6,674 participants), 26 on SARS (15,928), and 11 on MERS (3,095).

The COVID-19 studies included in the analysis consistently reported a benefit for the three interventions and had similar findings to studies of SARS and MERS.

Analysis of data from nine studies (across SARS, MERS and COVID-19, including 7,782 participants) looking at physical distance and virus transmission found that keeping a distance of over one metre from other people was associated with a much lower risk of infection compared with less than one metre (risk of infection when individuals stand more than a metre away from the infected individual was 3% vs 13% if within a metre), however, the modelling suggests for every extra metre further away up to three metres, the risk of infection or transmission may halve (figure 3). The authors note that the certainty of their evidence on physical distancing is moderate [1] and that none of the studies quantitatively evaluated whether distances of more than 2 metres were more effective, although meta-analyses provided estimates of risk.

Thirteen studies (across all three viruses, including 3,713 participants) focusing on eye protection found that face shields, goggles, and glasses were associated with lower risk of infection, compared with no eye covering (risk of infection or transmission when wearing eye protection was 6% vs 16% when not wearing eye protection). The authors note that the certainty of the evidence for eye coverings is low [1].

Evidence from 10 studies (across all three viruses, including 2,647 participants) also found similar benefits for face masks in general (risk of infection or transmission when wearing a mask was 3% vs 17% when not wearing a mask). Evidence in the study was looking mainly at mask use within households and among contacts of cases, and was also based on evidence of low certainty.

For healthcare workers, N95 and other respirator-type masks might be associated with a greater protection from viral transmission than surgical masks or similar (eg, reusable 12-16 layer cotton or gauze masks). For the general public, face masks are also probably associated with protection, even in non-health-care settings, with either disposable surgical masks or reusable 12-16 layer cotton ones. However, the authors note that there are concerns that mass face mask use risks diverting supplies from health-care workers and other caregivers at highest risk for infection.

They also stress that policy makers will need to quickly address access issues for face masks to ensure that they are equally available for all. “With respirators such as N95s, surgical masks, and eye protection in short supply, and desperately needed by healthcare workers on the front lines of treating COVID-19 patients, increasing and repurposing of manufacturing capacity is urgently needed to overcome global shortages”, says co-author Dr Derek Chu, Assistant Professor at McMaster University. “We also believe that solutions should be found for making face masks available to the general public. However, people must be clear that wearing a mask is not an alternative to physical distancing, eye protection or basic measures such as hand hygiene, but might add an extra layer of protection.”

The authors also stress the importance of using information about how acceptable, feasible, resource intense, and equally accessible to all the use of these interventions are when devising recommendations. “Across 24 studies of all three viruses including 50,566 individuals, most participants found these personal protection strategies acceptable, feasible, and reassuring, but noted harms and challenges including frequent discomfort and facial skin breakdown, increased difficulty communicating clearly, and perceived reduced empathy from care providers by those they were caring for”, says Dr Sally Yaacoub from the American University of Beruit in Lebanon.

According to co-author Karla Solo from McMaster University in Canada: “While our results provide moderate and low certainty evidence, this is the first study to synthesise all direct information from COVID-19 and, therefore, provides the currently best available evidence to inform optimum use of these common and simple interventions.”

Despite these important findings, the review has some limitations including that few studies assessed the effect of interventions in non-healthcare settings, and most evidence came from studies of SARS and MERS. Finally, the effect of duration of exposure on risk for transmission was not specifically examined.

Writing in a linked Comment, lead author Professor Raina MacIntyre (who was not involved in the study) from the Kirby Institute, University of New South Wales in Australia, describes the study as “an important milestone”, and writes, “For health­care workers on COVID­19 wards, a respirator should be the minimum standard of care. This study by Chu and colleagues should prompt a review of all guidelines that recommend a medical mask for health workers caring for COVID­19 patients. Although medical masks do protect, the occupational health and safety of health workers should be the highest priority and the precautionary principle applied.”

She continues, “[They] also report that respirators and multilayer masks are more protective than are single layer masks. This finding is vital to inform the proliferation of home­made cloth mask designs, many of which are single­layered. A well designed cloth mask should have water­resistant fabric, multiple layers, and good facial fit…Universal face mask use might enable safe lifting of restrictions in communities seeking to resume normal activities and could protect people in crowded public settings and within households.”

A personal handheld UV light may kill the novel coronavirus

0

US and Japanese universities collaborate on research that shows that UV light can be used to kill the novel coronavirus (SARS-CoV2)

When US President Donald Trump talked of a UV light inside the body to kill the Novel Coronavirus, he may have erred in the prescription but not the principle.

A personal, handheld device emitting high-intensity ultraviolet light to disinfect areas by killing the novel coronavirus is now feasible, according to researchers at Penn State, the University of Minnesota and two Japanese universities.

There are two commonly employed methods to sanitize and disinfect areas from bacteria and viruses — chemicals or ultraviolet radiation exposure. The UV radiation is in the 200 to 300 nanometer range and known to destroy the virus, making the virus incapable of reproducing and infecting. Widespread adoption of this efficient UV approach is much in demand during the current pandemic, but it requires UV radiation sources that emit sufficiently high doses of UV light. While devices with these high doses currently exist, the UV radiation source is typically an expensive mercury-containing gas discharge lamp, which requires high power, has a relatively short lifetime, and is bulky.

The solution is to develop high-performance, UV light emitting diodes, which would be far more portable, long-lasting, energy efficient and environmentally benign

The solution is to develop high-performance, UV light emitting diodes, which would be far more portable, long-lasting, energy efficient and environmentally benign. While these LEDs exist, applying a current to them for light emission is complicated by the fact that the electrode material also has to be transparent to UV light.

“You have to ensure a sufficient UV light dose to kill all the viruses,” said Roman Engel-Herbert, Penn State associate professor of materials science, physics and chemistry. “This means you need a high-performance UV LED emitting a high intensity of UV light, which is currently limited by the transparent electrode material being used.”

While finding transparent electrode materials operating in the visible spectrum for displays, smartphones and LED lighting is a long-standing problem, the challenge is even more difficult for ultraviolet light.

“There is currently no good solution for a UV-transparent electrode,” said Joseph Roth, doctoral candidate in Materials Science and Engineering at Penn State. “Right now, the current material solution commonly employed for visible light application is used despite it being too absorbing in the UV range. There is simply no good material choice for a UV-transparent conductor material that has been identified.”

Finding a new material with the right composition is key to advancing UV LED performance. The Penn State team, in collaboration with materials theorists from the University of Minnesota, recognized early on that the solution for the problem might be found in a recently discovered new class of transparent conductors. When theoretical predictions pointed to the material strontium niobate, the researchers reached out to their Japanese collaborators to obtain strontium niobate films and immediately tested their performance as UV transparent conductors. While these films held the promise of the theoretical predictions, the researchers needed a deposition method to integrate these films in a scalable way.

“We immediately tried to grow these films using the standard film-growth technique widely adopted in industry, called sputtering,” Roth said. “We were successful.”

This is a critical step towards technology maturation which makes it possible to integrate this new material into UV LEDs at low cost and high quantity. And both Engel-Herbert and Roth believe this is necessary during this crisis.

“While our first motivation in developing UV transparent conductors was to build an economic solution for water disinfection, we now realize that this breakthrough discovery potentially offers a solution to deactivate COVID-19 in aerosols that might be distributed in HVAC systems of buildings,” Roth explains. Other areas of application for virus disinfection are densely and frequently populated areas, such as theaters, sports arenas and public transportation vehicles such as buses, subways and airplanes.